Exploring Fluvoxamine in COVID-19 Treatment

This chapter analyzes the potential of fluvoxamine, an SSRI antidepressant, as a treatment for COVID-19, highlighting its efficacy in managing inflammation and reducing hospitalization rates. The discussion contrasts fluvoxamine with the controversial ivermectin, emphasizing the importance of robust clinical trials and public perception in the context of repurposed medications.